

Obstructive Sleep Apnoea/Hypopnoea Syndrome and Obesity Hypoventilation Syndrome Committee meeting 14

Date: 19/02/2020

Location: Boardroom, National Guideline Centre, 11 St Andrews Place,

Regent's Park, London, NW1 4LE

Minutes: Final

Committee members present:			
Martin Robinson (MR) (Chair)	(Present for items 1 – 5)		
Anita Simonds (AS) (Topic adviser)	(Present for items 1 – 5)		
Ama Johal (AJ)	(Present for items 1 – 5)		
Adrian Kendrick	(Present for items 1 – 5)		
Robert Koefman (RK)	(Present for items 1 – 5)		
Annabel Nickol (ANi)	(Present for items 1 – 5)		
Chris Rogers (CR)	(Present for items 1 – 5)		
Tahmina Siddiqui (TS)	(Present for items 1 – 5)		
lan Stone (IS)	(Present for items 1 – 5)		
Sophie West (SW)	(Present for items 1 – 5)		
lain Wheatley (IW)	(Present for items 1 – 5)		

In attendance:		
Catrina Charlton (CC)	Guidelines Commissioning Manager, NICE	(Present for items 4 – 5)
Catherine Baden-Daintree	Senior Medical Editor, NICE	(Present for items 1 – 5)
Stephanie Holderness (SH)	Project Manager, NGC	(Present for items 1 – 5)
Kate Kelley (KK)	Operations Director, NGC	(Present for items 1 – 5)
Sharangini Rajesh (SR)	Senior Research Fellow, NGC	(Present for items 1 – 5)
Audrius Stonkus (ASt)	Research Fellow, NGC	(Present for items 1 – 5)



David Wonderling (DW)	Head of Health	(Present for items 1 – 5)
	Economics, NGC	

Apologies:	
Carlos Sharpin	Guideline Lead, NGC
Ann Nevinson	Lay Member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fourteenth meeting on Obstructive Sleep Apnoea/Hypopnoea Syndrome and Obesity Hypoventilation Syndrome.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included reviewing all recommendations.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Chris Rogers	Lay member	Along with a colleague from The Sleep Apnoea Trust Association (SATA) I met with Jazz Pharmaceutical to understand their business in the UK. Meeting lasted one hour at the Holiday Inn, Peartree, Oxford in a meeting room we had booked for a SATA. Jazz Pharma are producing a drug for sleep apnoea. Drugs for sleep apnoea are not being covered in the	Direct non- financial. Professional and personal.	Non- specific. No action other than the process of open declaration



		guideline.		
Tahmina Siddiqui	GP	Meeting with Jazz Pharmaceutical at GP surgery. The aim was for Jazz Pharmaceutical to inform about their drug and to find the model of community sleep clinic I am currently running for my practice patients. The meeting was not related to anything I am doing on the NICE Guideline (drugs are excluded from the scope).	Direct – non financial. Professional and personal.	Non- specific. No action other than the process of open declaration
Annabel Nickol	Consultant respiratory and sleep physician in a tertiary referral centre	Meeting with representatives from Jazz Pharmaceutical, who are interested in learning about structuring of Neuro- and Respiratory Sleep services in the UK.	Direct – non financial. Professional and personal.	Non- specific. No action other than the process of open declaration

The Chair and a senior member of the Developer's team noted that the following members would not participate in a part of the meeting:

- Robert Koefman is unable to participate in recommendation discussions for diagnosis and assessment
- Ama Johal is unable to participate in recommendation discussions for oral devices

3. Minutes of the last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. The Committee made changes to the OSAHS Recommendations, OHS Recommendations and to the Overlap Syndrome Recommendations in the Short



version of the Guideline.

5. The Committee made changes to the Research Recommendations.

Any other business

This was the last meeting before the Guideline goes in for Consultation.

Date of next meeting: 15/07/2020

Location of next meeting: Boardroom, National Guideline Centre, 11 St Andrews

Place, Regent's Park, London, NW1 4LE